Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

Annals of Neurology

Volumn 68, Issue 5, 2010, Pages 693-702

  Pioro, Erik P ^a   Brooks, Benjamin Rix ^b   Cummings, Jeffrey ^c   Schiffer, Randolph ^a   Thisted, Ronald A ^d   Wynn, Daniel ^e   Hepner, Adrian ^f   Kaye, Randall ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e Consultants in Neurology ^*  (United States)

^f AVANIR PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTROMETHORPHAN; PLACEBO; QUINIDINE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FALLING; FATIGUE; FEMALE; HEADACHE; HUMAN; LIMB PAIN; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PSEUDOBULBAR AFFECT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SOCIAL STATUS; SOMNOLENCE; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AFFECTIVE SYMPTOMS; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; DEXTROMETHORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OXYGEN; QUINIDINE;

EID: 78249270418     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22093     Document Type: Article

References (37)

1. Dark FL, McGrath JJ, Ron MA,. Pathological laughing and crying. Aust N Z J Psychiatry 1996; 30: 472 - 479.
2. House A, Dennis M, Molyneux A, et al. Emotionalism after stroke. BMJ 1989; 298: 991 - 994.
3. Brooks N,. Personality change after severe head injury. Acta Neurochir Suppl (Wien) 1988; 44: 59 - 64.
4. Starkstein SE, Migliorelli R, Teson A, et al. Prevalence and clinical correlates of pathological affective display in Alzheimer-s disease. J Neurol Neurosurg Psychiatry 1995; 59: 55 - 60.
5. Jackson CE, Bryan WW,. Amyotrophic lateral sclerosis. Semin Neurol 1998; 18: 27 - 39.
6. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52: 1311 - 1323.
7. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009; 73: 1227 - 1233.
8. Feinstein A, Feinstein K, Gray T, O'Connor P,. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 1997; 54: 1116 - 1121.
9. Tateno A, Jorge RE, Robinson RG,. Pathological laughing and crying following traumatic brain injury. J Neuropsychiatry Clin Neurosci 2004; 16: 426 - 434.
10. Gallagher JP,. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989; 80: 114 - 117.
11. Schiffer R, Pope LE,. Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci 2005; 17: 447 - 454.
12. Parvizi J, Arciniegas DB, Bernardini GL, et al. Diagnosis and management of pathological laughter and crying. Mayo Clin Proc 2006; 81: 1482 - 1486.
13. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004; 63: 1364 - 1370.
14. Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006; 59: 780 - 787.
15. Choi DW,. Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res 1987; 403: 333 - 336.
16. Musacchio JM, Klein M, Paturzo JJ,. Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[3H]3-(-3-hydroxyphenyl)- N-(1-propyl)piperidine. Mol Pharmacol 1989; 35: 1 - 5.
17. Zhang Y, Britto MR, Valderhaug KL, et al. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992; 51: 647 - 655.
18. Holford NH, Coates PE, Guentert TW, et al. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration-effect relationships. Br J Clin Pharmacol 1981; 11: 187 - 195.
19. De, Ponti F, Poluzzi E, Montanaro N,. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000; 56: 1 - 18.
20. Brooks BR, Cummings J, Pioro EP, et al. Pharmacokinetic/pharmacodynamic modeling of dextromethorphan/quinidine for a study in pseudobulbar affect. Presented at: American Neurological Association-s 133rd Annual Meeting; September 21-24, 2008; Salt Lake City, Utah [abstract T 172].
21. Moore SR, Gresham LS, Bromberg MB, et al. A self report measure of affective lability. J Neurol Neurosurg Psychiatry 1997; 63: 89 - 93.
22. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293 - 299.
23. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121 - 127.
24. Beck AT, Steer RA, Brown GK., Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation, 1996.
25. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12: 233 - 239.
26. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473 - 483.
27. Smith RA, Berg JE, Pope LE, et al. Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler 2004; 10: 679 - 685.
28. Hausman J, Hall BH, Griliches Z,. Econometric models for count data with an application to the patents-R&D relationship. Econometrica 1984; 52: 909 - 938.
29. Frison L, Pocock SJ,. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 1992; 11: 1685 - 1704.
30. Wolf JK, Santana HB, Thorpy M,. Treatment of -emotional incontinence- with levodopa. Neurology 1979; 29: 1435 - 1436.
31. Udaka F, Yamao S, Nagata H, et al. Pathologic laughing and crying treated with levodopa. Arch Neurol 1984; 41: 1095 - 1096.
32. Schiffer RB, Herndon RM, Rudick RA,. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985; 312: 1480 - 1482.
33. Robinson RG, Parikh RM, Lipsey JR, et al. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993; 150: 286 - 293.
34. Seliger GM, Hornstein A, Flax J, et al. Fluoxetine improves emotional incontinence. Brain Inj 1992; 6: 267 - 270.
35. Andersen G, Vestergaard K, Riis JO,. Citalopram for post-stroke pathological crying. Lancet 1993; 342: 837 - 839.
36. Muller U, Murai T, Bauer-, Wittmund T, von, Cramon DY,. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj 1999; 13: 805 - 811.
37. Burns A, Russell E, Stratton-Powell H, et al. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry 1999; 14: 681 - 685.